Valneva will receive a $130 million upfront payment from Pfizer under its Lyme vaccine collaboration agreement. The companies entered a collaboration at the end of April 2020 to develop and commercialize Valneva’s Lyme disease vaccine candidate VLA15, which is currently in Phase II clinical studies. Under the agreement, Valneva and Pfizer will work together throughout the development of VLA15. Valneva is eligible to receive a total of $308 million cash payments including the $130 million upfr...